Literature DB >> 32848012

Relationship between smoking and ALS: Mendelian randomisation interrogation of causality.

Sarah Opie-Martin1, Robyn E Wootton2,3,4, Ashley Budu-Aggrey2, Aleksey Shatunov1, Ashley R Jones1, Alfredo Iacoangeli1, Ahmad Al Khleifat1, George Davey-Smith4, Ammar Al-Chalabi5,6.   

Abstract

OBJECTIVE: Smoking has been widely studied as a susceptibility factor for amyotrophic lateral sclerosis (ALS), but results are conflicting and at risk of confounding bias. We used the results of recently published large genome-wide association studies and Mendelian randomisation methods to reduce confounding to assess the relationship between smoking and ALS.
METHODS: Two genome-wide association studies investigating lifetime smoking (n=463 003) and ever smoking (n=1 232 091) were identified and used to define instrumental variables for smoking. A genome-wide association study of ALS (20 806 cases; 59 804 controls) was used as the outcome for inverse variance weighted Mendelian randomisation, and four other Mendelian randomisation methods, to test whether smoking is causal for ALS. Analyses were bidirectional to assess reverse causality.
RESULTS: There was no strong evidence for a causal or reverse causal relationship between smoking and ALS. The results of Mendelian randomisation using the inverse variance weighted method were: lifetime smoking OR 0.94 (95% CI 0.74 to 1.19), p value 0.59; ever smoking OR 1.10 (95% CI 1 to 1.23), p value 0.05.
CONCLUSIONS: Using multiple methods, large sample sizes and sensitivity analyses, we find no evidence with Mendelian randomisation techniques that smoking causes ALS. Other smoking phenotypes, such as current smoking, may be suitable for future Mendelian randomisation studies. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Mesh:

Year:  2020        PMID: 32848012     DOI: 10.1136/jnnp-2020-323316

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  4 in total

Review 1.  A review of Mendelian randomization in amyotrophic lateral sclerosis.

Authors:  Thomas H Julian; Sarah Boddy; Mahjabin Islam; Julian Kurz; Katherine J Whittaker; Tobias Moll; Calum Harvey; Sai Zhang; Michael P Snyder; Christopher McDermott; Johnathan Cooper-Knock; Pamela J Shaw
Journal:  Brain       Date:  2022-04-29       Impact factor: 15.255

2.  Statin Medications and Amyotrophic Lateral Sclerosis Incidence and Mortality.

Authors:  Marc G Weisskopf; Joseph Levy; Aisha S Dickerson; Sabrina Paganoni; Maya Leventer-Roberts
Journal:  Am J Epidemiol       Date:  2022-06-27       Impact factor: 5.363

3.  Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis.

Authors:  Alexander G Thompson; Kevin Talbot; Martin R Turner
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-09-13       Impact factor: 10.154

4.  Application of a bioinformatic pipeline to RNA-seq data identifies novel virus-like sequence in human blood.

Authors:  Marko Melnick; Patrick Gonzales; Thomas J LaRocca; Yuping Song; Joanne Wuu; Michael Benatar; Björn Oskarsson; Leonard Petrucelli; Robin D Dowell; Christopher D Link; Mercedes Prudencio
Journal:  G3 (Bethesda)       Date:  2021-09-06       Impact factor: 3.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.